Search results for "FIBRILLATION"

showing 10 items of 509 documents

Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success.

2015

Background— In the meantime, catheter ablation is widely used for the treatment of persistent atrial fibrillation (AF). There is a paucity of data about long-term outcomes. This study evaluates (1) 5-year single and multiple procedure success and (2) prognostic factors for arrhythmia recurrences after catheter ablation of persistent AF using the stepwise approach aiming at AF termination. Methods and Results— A total of 549 patients with persistent AF underwent de novo catheter ablation using the stepwise approach (2007–2009). A total of 493 patients were included (Holter ECGs ≥every 6 months). Mean follow-up was 59±16 months with 2.1±1.1 procedures per patient. Single and multiple procedu…

AdultMaleReoperationmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentCatheter ablationKaplan-Meier EstimateDisease-Free SurvivalYoung AdultSex FactorsHeart RatePredictive Value of TestsRecurrenceRisk FactorsPhysiology (medical)Internal medicineHeart rateAtrial FibrillationmedicineTachycardia SupraventricularHumans610 Medicine & healthAgedRetrospective StudiesAged 80 and overbusiness.industryAtrial fibrillationRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeAtrial FlutterPredictive value of testsPersistent atrial fibrillationMultivariate AnalysisCardiologyCatheter AblationElectrocardiography AmbulatoryFemaleCardiology and Cardiovascular MedicinebusinessStepwise approachAnti-Arrhythmia AgentsAtrial flutterFollow-Up StudiesCirculation. Arrhythmia and electrophysiology
researchProduct

Leisure-time cross-country skiing and risk of atrial fibrillation and stroke:a prospective cohort study

2020

[No Abstract]

AdultMaleRiskmedicine.medical_specialtyEpidemiologyLeisure timeMEDLINEaivohalvausLeisure ActivitiesSkiingAtrial FibrillationmedicineHumansatrial fibrillationProspective StudiesProspective cohort studyStrokeFinlandCross countrybusiness.industryAtrial fibrillationleisure-timeMiddle Agedmedicine.diseaseeteisvärinähiihtostrokeStrokeEmergency medicineCardiology and Cardiovascular Medicinebusinesscross-country skiingvapaa-aika
researchProduct

A new risk score to assess atrial fibrillation risk in hypertensive patients (ESCARVAL-RISK Project.

2020

AbstractThis study aimed to assess atrial fibrillation (AF) incidence and predictive factors in hypertensive patients and to formulate an AF risk assessment score that can be used to identify the patients most likely to develop AF. This was a cohort study of patients recruited in primary healthcare centers. Patients aged 40 years or older with hypertension, free of AF and with no previous cardiovascular events were included. Patients attended annual visits according to clinical practice until the end of study or onset of AF. The association between AF incidence and explanatory variables (age, sex, body mass index, medical history and other) was analyzed. Finally, 12,206 patients were includ…

AdultMaleRiskmedicine.medical_specialtyTime FactorsCardiologylcsh:Medicine030204 cardiovascular system & hematologyRisk AssessmentArticleCohort Studies03 medical and health sciencesSex Factors0302 clinical medicineInternal medicineAtrial FibrillationmedicineHumansObesity030212 general & internal medicinelcsh:ScienceAgedHeart FailureMultidisciplinaryFramingham Risk Scorebusiness.industryIncidenceIncidence (epidemiology)lcsh:RHazard ratioAge FactorsAtrial fibrillationMiddle Agedmedicine.diseaseConfidence intervalRisk factorsResearch DesignHypertensionFemalelcsh:QbusinessRisk assessmentBody mass indexFollow-Up StudiesForecastingCohort study
researchProduct

Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: The use of fixed sub-therap…

2012

No data are available regarding the management of cancer patients requiring interruption of long-term vitamin-K antagonist (VKA) therapy. For this purpose, we tested the efficacy and safety of fixed doses of low-molecular weight heparin (LMWH) in substitution of VKA because of invasive procedures or chemotherapy-induced thrombocytopenia. In cancer patients on VKA, therapy was discontinued 5 ± 1 days before surgery or chemotherapy. Heparin was given at prophylactic dosage in patients at low risk and at fixed subtherapeutic doses (3,800 or 4,000 UI anti-FXa, b.i.d.) in those at high-risk for thrombosis. LMWH was reinitiated 12 hr after surgery and VKA the day after. In patients receiving chem…

AdultMaleRiskmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentLow molecular weight heparinAntineoplastic AgentsHemorrhagelow-molecular weight heparin (LMWH); long-term vitamin-K antagonist (VKA) therapy; cancer patientsSettore MED/15 - Malattie Del SanguePostoperative ComplicationsNeoplasmsThromboembolismAtrial FibrillationHumansThrombophiliaMedicinecancer thrombocytopenia low molecular weight heparinProspective StudiesProspective cohort studyAgedAged 80 and overChemotherapybusiness.industryIncidenceWarfarinAnticoagulantsCancerHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombocytopeniaThrombosisSurgeryClinical trialHeart Valve ProsthesisAnesthesialow-molecular weight heparin (LMWH)FemaleWarfarinlong-term vitamin-K antagonist (VKA) therapycancer patientsbusinessmedicine.drugAmerican Journal of Hematology
researchProduct

Prospective risk stratification of sudden cardiac death in Marfan's syndrome.

2013

Marfan syndrome (MFS) is a variable, autosomal-dominant disorder of the connective tissue. In MFS serious ventricular arrhythmias and sudden cardiac death (SCD) can occur. The aim of this prospective study was to reveal underlying risk factors and to prospectively investigate the association between MFS and SCD in a long-term follow-up.77 patients with MFS were included. At baseline serum N-terminal pro-brain natriuretic peptide (NT-proBNP), transthoracic echocardiogram, 12-lead resting ECG, signal-averaged ECG (SAECG) and a 24-h Holter ECG with time- and frequency domain analyses were performed. The primary composite endpoint was defined as SCD, ventricular tachycardia (VT), ventricular fi…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyCardiomyopathyVentricular tachycardiaRisk AssessmentSudden cardiac deathMarfan SyndromeYoung AdultInternal medicineClinical endpointMedicineHumanscardiovascular diseasesProspective StudiesUltrasonographybusiness.industryHazard ratioMiddle Agedmedicine.diseaseSignal-averaged electrocardiogramDeath Sudden CardiacVentricular fibrillationCardiologyFemaleTransthoracic echocardiogramCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesInternational journal of cardiology
researchProduct

Comparative Analysis of Patients with Acute Coronary and Cerebrovascular Syndromes from the National French Hospitalization Health Care System Databa…

2010

<i>Background:</i> Nationwide evaluations of the epidemiology of acute coronary syndrome (ACS) or cerebrovascular syndrome (CVS) are scarce. We aimed to analyze nationwide French data on patients referred to hospital for either ACS or CVS. <i>Methods:</i> Using the French national hospital discharge diagnosis records, all patients hospitalized between 2005 and 2008 with a diagnosis of ACS and CVS based on the ICD-10 were identified. We analyzed vascular risk factors and early outcomes in patients with a single hospitalization for ACS or CVS or for both ACV and CVS in a 2-month time window. <i>Results:</i> 1,187,643 patients were recorded. Among these, 638…

AdultMalemedicine.medical_specialtyAcute coronary syndromePediatricsAdolescentEpidemiologyHypercholesterolemiaMyocardial Infarctionfluids and secretionsRisk FactorsInternal medicineDiabetes mellitusAtrial FibrillationEpidemiologyDiabetes MellitusmedicineHumansHospital MortalityObesityRegistriesMyocardial infarctionAcute Coronary SyndromeStrokeAgedAged 80 and overInpatientsbusiness.industryAbsolute risk reductionAtrial fibrillationMiddle Agedequipment and suppliesmedicine.diseaseStrokeCerebrovascular DisordersHypertensionMyocardial infarction complicationsFemaleFranceNeurology (clinical)businessNeuroepidemiology
researchProduct

Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxida…

2008

Background and objective: Atrial fibrillation (AF) is the most common cardiac arrhythmia. Recent studies suggest there is an angiotensin II-dependent increase in adhesion molecules and oxidative stress parameters during AF. These alterations appear to contribute to inflammatory and prothrombotic changes in the atrial endocardium (‘endocardial remodelling’), suggesting that patients with increased levels of these factors might be at risk of thromboembolic events. The purpose of the CREATIVE-AF (Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients with Persistent Atrial Fibrillation) trial is to prove the principle concept that blockade of angiotensin II type 1 r…

AdultMalemedicine.medical_specialtyAdolescentEndpoint DeterminationTetrazolesmedicine.disease_causeYoung AdultIrbesartanVon Willebrand factorDouble-Blind MethodInternal medicineAtrial FibrillationmedicineHumansPharmacology (medical)Cell adhesionAgedCross-Over StudiesbiologyCell adhesion moleculebusiness.industryPatient SelectionBiphenyl CompoundsAtrial fibrillationGeneral MedicineIrbesartanMiddle Agedmedicine.diseaseAngiotensin IICrossover studyOxidative StressData Interpretation StatisticalSample SizeCardiologybiology.proteinFemalebusinessAngiotensin II Type 1 Receptor BlockersCell Adhesion MoleculesOxidative stressBiomarkersmedicine.drugClinical drug investigation
researchProduct

Effect of intravenous flecainide on atrial vulnerability in man.

1985

Sixteen patients were investigated by means of programmed atrial stimulation at 2 different driving rates: 100/min and 120/min. All patients had an increased atrial vulnerability at both driving rates. After the administration of intravenous flecainide (1 mg/kg bodyweight as a bolus, followed by the same amount infused over a period of 20 minutes), the increased vulnerability was abolished in 11 and 9 patients, respectively. In the remaining patients the rate of induced atrial tachyarrhythmia decreased. These findings correlate with a significant prolongation of the effective refractory period of the right atrium and a corresponding significant shortening of its relative refractory period. …

AdultMalemedicine.medical_specialtyAdolescentRefractory Period ElectrophysiologicalRefractory periodElectrocardiographyBolus (medicine)PiperidinesInternal medicinemedicineHumansPharmacology (medical)Infusions ParenteralHeart AtriaFlecainideAgedFlecainidemedicine.diagnostic_testbusiness.industryAtrial vulnerabilityEffective refractory periodAtrial fibrillationArrhythmias CardiacMiddle Agedmedicine.diseaseAtrial FlutterAnesthesiaCardiologyFemalebusinessElectrocardiographyAnti-Arrhythmia AgentsAtrial fluttermedicine.drugDrugs
researchProduct

Effect of intravenous flecainide on atrial vulnerability in man.

1983

Sixteen patients were investigated by means of programmed atrial stimulation at two different driving rates: 100 and 120/min. All patients had an increased atrial vulnerability at both driving rates. After intravenous flecainide application (1 mg/kg body weight as a bolus followed by the same amount given by infusion over a period of 20 min) the increased vulnerability was abolished in 11 and 9 patients respectively. In the remaining patients the rate of induced atrial tachyarrhythmia decreased. These findings correlate with a significant prolongation of the effective refractory period of the right atrium and a significant shortening of the relative refractory period of the right atrium. It…

AdultMalemedicine.medical_specialtyAdolescentRefractory periodBody weightElectrocardiographyBolus (medicine)PiperidinesHeart Conduction SystemInternal medicineDrug DiscoveryAtrial FibrillationmedicineHumanscardiovascular diseasesFlecainideGenetics (clinical)AgedFlecainidebusiness.industryAtrial vulnerabilityEffective refractory periodCardiac Pacing ArtificialGeneral MedicineAtrial arrhythmiasMiddle Agedmedicine.anatomical_structureAtrial Fluttercardiovascular systemCardiologyMolecular MedicineRight atriumFemalebusinessAnti-Arrhythmia Agentsmedicine.drugKlinische Wochenschrift
researchProduct

European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring

2014

Given the increasing use of ambulatory blood pressure monitoring (ABPM) in both clinical practice and hypertension research, a group of scientists, participating in the European Society of Hypertension Working Group on blood pressure monitoring and cardiovascular variability, in year 2013 published a comprehensive position paper dealing with all aspects of the technique, based on the available scientific evidence for ABPM. The present work represents an updated schematic summary of the most important aspects related to the use of ABPM in daily practice, and is aimed at providing recommendations for proper use of this technique in a clinical setting by both specialists and practicing physici…

AdultMalemedicine.medical_specialtyAmbulatory blood pressureAdolescentPhysiologyMEDLINEPharmacyWhite coat hypertensionPractice PatternsBlood Pressure MonitoringMasked HypertensionAtrial FibrillationAmbulatoryInternal MedicinemedicineHumansambulatory blood pressure monitoring arterial hypertension clinic blood pressure measurement clinical indications guidelines home blood pressure measurement practice recommendationsObesityPractice Patterns Physicians'ChildIntensive care medicineReimbursementPhysicians'business.industryMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring Ambulatorymedicine.disease3. Good healthMasked HypertensionBlood pressureHypertensionPosition paperFemaleCardiology and Cardiovascular MedicinebusinessSoftwareWhite Coat HypertensionJournal of Hypertension
researchProduct